BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20230626T080000
DTEND;TZID=UTC:20230626T100000
DTSTAMP:20230613T214058Z
CREATED:20230613T214058Z
LAST-MODIFIED:20230613T214058Z
UID:25240-1687766400-1687773600@scienceinboston.com
SUMMARY:The Investment Climate’s Impact on Biotechs\, Tech Transfer & Pipeline
DESCRIPTION:Private biotechs are operating in a fundraising environment where access to capital is limited. This has led to a spike in shutdowns\, restructurings\, reductions-in-force\, and “strategic alternatives” across the industry that one VC investor recently cited. Smaller and more emerging companies may be wondering how to respond\, what nontraditional cash\, partnering\, and business opportunities exist\, and how to continue to access funding. For example\, “Should we extend our series A or go for a series B?” The market downturn is likewise impacting tech transfer\, company spin-out\, and the drug discovery pipeline. \nWhere are innovation and company creation pausing due to tight cash flows and cautious investors? Listen to a panel of speakers who can comment on these questions and offer insights from investor\, university\, and biotech perspectives.
URL:https://scienceinboston.com/event/the-investment-climates-impact-on-biotechs-tech-transfer-pipeline/
END:VEVENT
END:VCALENDAR